cyanoethyloxycarbonyloxy succinimide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: cyanoethyloxycarbonyloxy succinimide
• 英文别名: 2-Cyanoethyl (2,5-dioxopyrrolidin-3-yl) carbonate
• 化学式: C₈H₈N₂O₅
• 分子量: 212.162
• InChiKey: IUIBPRVSJRGWGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N,N'-二琥珀酰亚胺基碳酸酯 、 3-羟基丙腈 在 吡啶 、 sodium chloride 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 以95%的产率得到cyanoethyloxycarbonyloxy succinimide
  参考文献：
  名称：

  Oligonucleotide protecting groups

  摘要：

  本发明的化合物具有一般式##STR1##，可用作有机合成过程中保护胺基、胍基、酰胺基或羟基的试剂。具体而言，这些化合物在寡核苷酸合成过程中非常有用，可用于保护核碱基胺基以及用于将功能基团连接到寡核苷酸的缚合胺基。

  公开号：

  US06166239A1

文献信息

• SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI
  申请人：DELIVERSIR LTD.

  公开号：US20160039850A1

  公开（公告）日：2016-02-11

  The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.

  本发明涉及一种新型递送系统，用于将治疗剂递送到活细胞中，更具体地说，涉及设计用于靶向和/或穿透细胞或其他感兴趣目标的新型化学基团，进一步能够将治疗剂结合到这些细胞中以进行递送，并涉及含有相同化学基团的递送系统。
• Nuclease resistant chimeric oligonucleotides
  申请人：ISIS Pharmaceuticals, Inc.

  公开号：US20030158403A1

  公开（公告）日：2003-08-21

  The present invention relates to novel nuclease-resistant oligomeric compounds and to novel methods for increasing the nuclease resistance of oligomeric compounds. In preferred embodiments of the invention, the oligomeric compounds comprise at least one modified nucleoside containing a modified sugar moiety at either the 3′ or 5′ terminus of the oligomeric compound, and further comprise at least one internucleoside linking group that is other than phosphodiester. Other preferred embodiments of the invention include methods of enhancing the nuclease resistance of oligomeric compounds comprising incorporating at least one modified nucleoside containing a modified sugar moiety at either the 3′ or 5′ terminus of an oligomeric compound.

  本发明涉及新型核酸酶抗性寡聚合物化合物以及增加寡聚合物化合物核酸酶抗性的新方法。在本发明的优选实施例中，寡聚合物化合物包括至少一个含有修饰糖基团的修饰核苷酸，该修饰核苷酸位于寡聚合物化合物的3'端或5'端，而且还包括至少一个不是磷酸二酯的核苷酸之间连接的核苷酸连接基团。本发明的其他优选实施例包括增强寡聚合物化合物核酸酶抗性的方法，其中包括将至少一个含有修饰糖基团的修饰核苷酸合并到寡聚合物化合物的3'端或5'端。
• System for delivering therapeutic agents into living cells and cells nuclei
  申请人：Segev David

  公开号：US20060160763A1

  公开（公告）日：2006-07-20

  A novel class of oligomeric compounds designed for forming conjugates with biologically active substances and delivering these substances to a desired bodily target are disclosed. Novel conjugates of these oligomeric compounds and biologically active moieties, pharmaceutical compositions containing such conjugates, and uses thereof as delivery systems for delivering the biologically active substances to a desired target are further disclosed. Processes of preparing the conjugates and the oligomeric compounds and novel intermediates designed for and used in these processes are also disclosed.

  本发明披露了一种新型寡聚化合物，旨在与生物活性物质形成共轭物，并将这些物质传递到所需的身体靶点。本发明还披露了这些寡聚化合物和生物活性基团的新型共轭物，包含这种共轭物的药物组合物以及将其用作传递生物活性物质到所需靶点的传递系统的用途。本发明还披露了制备共轭物和寡聚化合物的过程以及设计和用于这些过程的新型中间体。
• Guanidinium functionalized oligomers and methods
  申请人：——

  公开号：US20030092046A1

  公开（公告）日：2003-05-15

  The present invention provides oligomers which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the nucleoside moieties of the oligomer is modified to include a guanidinium group. These oligomers are useful for diagnostic, therapeutic and investigative purposes.

  本发明提供了寡核苷酸，它们与RNA或DNA的选定序列具有特异性杂交性，其中至少一个核苷酸基团被修饰以包括一种鸟氨酸基团。这些寡核苷酸对于诊断、治疗和调查目的非常有用。
• GUANIDINIUM FUNCTIONALIZED OLIGOMERS AND METHODS
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：EP1206574A2

  公开（公告）日：2002-05-22